




RealRate

PHARMACEUTICAL 2019

Aimmune Therapeutics Inc
Rank 106 of 361



The relative strengths and weaknesses of Aimmune Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aimmune Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Aimmune Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 324%, being 74% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	312,619
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	38,012
Liabilities, Non-Current	2,596
Other Assets	608
Other Compr. Net Income	0
Other Expenses	61
Other Liabilities	0
Other Net Income	4,650
Other Revenues	0
Property and Equipment	26,328
Research and Development	133,420
Selling, General and Administrative Expense	81,921

Output Variable	Value in 1000 USD
Assets	339,555
Liabilities	40,608
Expenses	215,402
Revenues	0
Stockholders Equity	298,947
Net Income	-210,752
Comprehensive Net Income	-210,752
BaseVar	300,108
ECR before LimitedLiability	232%
Economic Capital Ratio	324%